Summary We have studied the actions of C-1 311, an imidazoacridinone analogue with potent in vivo antitumour activity, against a human tumour line (HeLa S3), in an examination of the events associated with the lethality of this agent. Continuous exposures (24 h) induced complete G2 arrest, although the concentration range of this effect was narrow, with elevation of the drug level inducing additional and increasing impediment to S-phase transit. Acute treatments (3 h) revealed that cells exposed to drug levels, which first induced persistent G2 arrest (0.5 jug ml-1), subsequently died from this compartment, while doses exceeding these levels (1.0 ig ml-'), paradoxically, did not cause the same extensive cell death. We explain our findings on the proposition that this particular mode of cell death is dependent upon inappropriate activation of the primed mitotic machinery-specifically the hyperphosphorylated p34cdc2/cyclin B complex-assembled within G2, but that impediment to genomic replication at higher doses inhibits assembly of this complex, and hence prevents cell death. Our results demonstrate that high dose does not necessarily correlate with increased cell death, while at the same time providing further evidence for the importance of events normally associated with the G2/M transition in DNA damage-induced tumour cell death.
Imidazoacridinones constitute a new class of antineoplastic agent, whose major representatives (including the lead compound designated C-1311) possess potent anti-tumour activity against a range of murine neoplasms (Cholody et al., 1992; Kusnierczyk et al., 1994) and human tumour xenografts in nude mice (Augustin et al., 1996) , in addition to significant in vitro cytotoxicity against both murine leukaemia cells (Cholody et al., 1992) and the human tumour lines of the National Cancer Institute (NCI) screen. C-1311 has recently been accepted for clinical trials in the UK.
Recent in vitro studies have identified the imidazoacridinones as topoisomerase II poisons (Skladanowski et al., 1996) , and three major representatives (C-1311, C-1310, C-1263) have been shown to be potent inhibitors of L1210 (murine leukaemia) cell cycle progression, causing selective accumulation in the G2 phase (i.e. G2 block) (Augustin et al., 1996) . This cellular response is universally associated with the action of DNA-damaging agents, including the topoisomerase II inhibitors (Kimler et al., 1978; Konopa, 1988; Lock and Ross, 1990a; O'Connor et al., 1991; Sorenson and Eastman, 1988b; Tounekti et al., 1993) , and represents activation of a DNA damage cell cycle checkpoint, whose engagement delays segregation of damaged chromosomes, thereby preventing mitotic catastrophe, and affording the cell opportunity for repair (Al-Khodairy and Carr, 1992; Hartwell and Weinert, 1989; Murray, 1994; Murray, 1992; Weinert and Lydall, 1993) . The biochemical basis of this cytostatic effect is relatively well understood, although the mechanism by which these agents actually effect cell killing, in which anti-tumour activity resides, remains comparatively obscure.
Reports of rapid or immediate cell death secondary to exposure to DNA-damaging agents (i.e. cell death without prior cycle arrest) have been made. However, these events are apparently restricted to cell types with a particular propensity for this response (Bertrand et al., 1991b (Bertrand et al., , 1993 Del Bino et al., 1990; Kaufmann et al., 1989; Radford et al., 1994) , or dependent upon the integrity of a p53-dependent programmed cell death pathway (Clarke et al., 1993; Lowe et al., 1993) , which is itself only manifest in certain, mainly lymphoid, cell types (Fan et al., 1994; O'Connor et al., 1993b; Slichenmyer et al., 1993) .
The appearance of cells arrested in the G2 phase has been shown to precede cell disintegration in many cell lines exposed to various DNA-damaging agents (Evans and Dive, 1993; Kim et al., 1993; Kruman et al., 1991; Lock and Ross, 1990b; Ormerod et al., 1994; Skladanowski and Konopa, 1993; Sorenson and Eastman, 1988a; Warters, 1992; Yamagishi et al., 1993) , suggesting that cycle arrest is an essential intermediate in drug action. Consequently, considerable importance has been placed upon the role of events normally associated with the G2/M transition in the death mechanism Bertrand et al., 1991a; Eastman, 1990; Fotedar et al., 1995; Rubin et al., 1993; Shi et al., 1994; Sorenson et al., 1990) , leading to the proposition that inappropriate or aberrant mitotic events may actually cause cell death.
The G2/M transition is universally controlled in mammalian systems by p34cdc2 kinase (Norbury and Nurse, 1992) , the activity of which is principally regulated by association with cyclin B (Pines and Hunter, 1989 ) and a complex series of phosphorylation/dephosphorylation reactions (Draetta and Beach, 1988) . Cyclin A is also implicated in association with both p34cdc2 and one of a family of related protein kinases (Meyerson et al., 1992) , identified as p33cdk2 (Elledge et al., 1992; Rosenblatt et al., 1992) . Mitotic progression is ultimately achieved by final activation of the p34cdc2/cyclin B complex through dephosphorylation of p34cdc2 at threonine 14 and tyrosine 15, and it is inhibition of this tyrosine dephosphorylation (Lock, 1992; Lock and Keeling, 1993; O'Connor et al., 1993a) , with concomitant suppression of p34CdC2 kinase activity (Lock and Ross, 1990a; O'Connor et al., 1992; Tsao et al., 1992) , which effects the premitotic cell cycle arrest induced by DNA-damaging agents.
At the molecular level, the proposition that (aberrant) mitotic events cause cell death is amply supported by recent evidence. Activation (tyrosine dephosphorylation) of p34cdc2 kinase at inappropriate times during the cell cycle leads to cell death (Shi et al., 1994 (Fotedar et al., 1995) . Similarly, activation of p34cdc2 and p33cdk2 by methylxanthines and purine analogues induces cell death in arrested HeLa cells, the effect being accompanied by an increase in histone HI kinase activity to near mitotic levels (Meikrantz et al., 1994) . Indeed, the release of cells from DNA damage-induced G2 arrest into cell death is accompanied by an increase in p34cdc2 kinase activity (Lock and Keeling, 1993; Lock and Ross, 1990b) and is promoted or potentiated by the same agents known to cause premature mitosis, whose actions enhance p34Cdc2 tyrosine dephosphorylation Hain et al., 1993; Lock et al., 1994; Steinmann et al., 1991; Tam and Schlegel, 1992) . It seems likely then that this particular mode of cell death: (1) is dependent upon assembly of the primed mitotic machinery, specifically the hyperphosphorylated p34cdc2/cyclin B complex; and (2) Cultures were dosed as described. After drug exposure, cultures were either submitted for analysis or the culture medium aspirated, the monolayer washed with prewarmed PBS and incubation continued in fresh medium for up to a total of 96 h, at which point the same analyses were conducted.
Flow cytometry Cells were harvested by gentle trypsinisation and combined with any non-adherent cells contained within the aspirated medium, which also served to neutralise the trypsin action. The cells were collected by centrifugation (400 g, 5 min) and resuspended in PBS. An aliquot of this suspension was further diluted with PBS and submitted for cell sizing; 5000 cells were analysed. Nuclei from the remainder of the suspension were isolated and stained with propidium iodide by the method of Vindel0v et al. (1983) . Nuclear fluorescence (DNA content) and forward light scatter (cell or nuclear volume) were recorded for each population, with doublet discrimination, using an EPICS Profile-II flow cytometer (Coulter Electronics Inc., Hialeah, FL, USA). The number of nuclei present in each (constant volume) sample was counted (concurrent with fluorescence and light scatter recordings) to give an indication of the cell density in each culture. Not less than 10 000 nuclei were processed per sample. Cell cycle phase distributions and the number of sub-G, events (expressed as a percentage of total events) were obtained, as necessary, by decomposition of single parameter DNA content frequency histograms using the 'Cytologic' software package (Coulter Electronics Inc.).
Growth inhibition assay Cells were grown in 6-well culture plates for 24 h from a seeding density of -5 x 104 cells per well. Cultures were dosed as described and incubation continued for a further 72 h, at which point the culture medium was removed, the monolayers washed with prewarmed PBS, and the cells harvested by gentle trypsinisation. Cell number was determined with a Model ZM Coulter Counter (Coulter Electronics Inc.) and the percentage of growth inhibition was calculated as follows, after the method of Bhuyan et al., (1992) : 100-100 x [(cell number in treated well -cells inoculated) (cell number in control well -cells inoculated)]. The 50% growth inhibitory concentration (IC50) was determined by interpolation of the resultant dose-response curves.
Clonogenic survival assay Reproductive capacity was assessed by colony-forming assay. Cells in exponential growth were washed twice with prewarmed PBS and resuspended in growth medium. Cell density was determined and adjusted such that a known number (-1000 cells) were seeded into each well of a 6-well culture plate in 2 ml of medium. Cells were allowed to grow for 24 h before being dosed as described. After 3 h drug exposure, the medium was removed and the cells washed with prewarmed drug-free medium. Fresh medium was added and incubation continued for a further 5 days. Colonies were stained with 2% crystal violet in methanol and counted. Reproductive capacity was expressed as a percentage of the cloning efficiency of controls.
MTT cleavage assay Cell survival was assessed by MTT cleavage assay (Mosmann, 1983) . Cells were seeded in 96-well culture plates at -4000 cells per well in 100 ,ul of growth medium and incubated at 37°C for 24 h, at which time the medium was removed and replaced by complete medium (100 ,ul) containing C-1 311. After 3 h, the medium was aspirated and the monolayers washed with prewarmed PBS. Fresh medium (100 ,ul) and 2 ). The IC50 was calculated as 0.018+0.003 jg ml -' (n = 4). This value is in broad agreement with the work of Cholody et al. (1992) and Augustin et al. (1996) , and indicates that HeLa and L1210 murine leukaemia cells share a similar sensitivity to the growth-inhibitory activity of the compound. Figure 3a and the corresponding cell cycle phase distributions are presented as Table I .
Cultures treated with C-1311 at 0.01 i,g ml-' showed only a marginal deviation from control cell cycle distribution. Exposure to C-1311 at 0.05 ,ug ml-' induced a conspicuous perturbation of cell cycle progression, however. A marked increase in the proportion of cells with a G2 phase character, and a significant reduction in cell number over control was observed, defining a G2 phase accumulation. Given that exposure time was selected to be marginally greater than cycle time, it was supposed that the observed G1 population was derived from cells having recently made the G2/M transition, and having passed the G2 accumulation point, signifying either that G2 transit time was extended, the progression delay was of a finite duration, or that some cells did not arrest at the accumulation point (i.e. an incomplete or 'leaky' cell cycle arrest). No slowing of S-phase transit was apparent. Treatment at 0.1 jug ml-' yielded a culture composed almost entirely of cells with G2 phase character. This, together with the albeit total absence of cells from the G, and S-phases indicated a complete and preferential G2 arrest. Elevation of drug levels beyond this concentration resulted in the induction of an additional S-phase accumulation, with increasing concentration producing accumulations earlier in phase.
Exponentially growing asynchronous cultures of normal human diploid fibroblasts were continuously exposed to C-1311 for 48 h. The agent induced the same sequence of cycle perturbations, and at similar concentrations, as in HeLa cells, although in all cases a G1 phase arrest accompanied the late cycle accumulations (Figure 3b ; Table II ). Nuclear and cellular volume distributions were consistent with the reported perturbations of cell cycle (data not shown).
Treatment outcomes following acute exposures Exponentially growing HeLa S3 cultures were exposed to C-131 1 at concentrations of 0.01 -1.0 jug ml -for 3 h, before transfer into drug-free medium for up to a total of 96 h. Histograms of nuclear DNA content obtained throughout this treatment matrix are shown as Figure 4 .
While untreated cultures exhibited typically unperturbed DNA content distributions throughout the course of the experiment, treatment with C-1311 at 0.01, 0.05, or 0.1 jIg ml-' induced modest late cycle phase accumulations, which were maximal at 12 h. These cultures recovered control cell cycle distributions within the time course of the experiment and cell number increased correspondingly. These cultures were subject to a transient or incomplete G2 block, which was rapidly overcome, thus representing only a minor impediment to expansion of the culture. Exposure to C-1311 at 0.5 ,ug ml-1 induced an overt and progressive disturbance of cell cycle distribution, however. Almost complete absence of cells with a G, character at 12 h signified a strict G2 block, confirmed by an all but 'pure' G2 population at 24 h. By 48 h, this arrested population was accompanied by considerable nuclear debris (sub-G1 signal) signifying extensive degradation of the culture. All cells arrested in G2 phase at 48 h were subsequently lost, such that by 96 h only nuclear debris remained. Treatment at a concentration of 1.0 jMg ml-' also produced frank perturbations of cell cycle distribution, but with a markedly different outcome. In contrast to treatment at 0.5 jug ml-', these cultures were composed predominantly of S-phase cells at 24 h and, although these cells attained approximate G2 DNA content character within a further 24 h, the absence of nuclear debris at this time was striking. Indeed, by the end of the experiment (96 h), there was only limited evidence of cellular disintegration. Cell and nuclear volume distribu- Reproductive capacity and cellular survival at 96 h, as assessed by colony-forming ability and MTT cleavage following the same drug exposures, were examined in parallel with this flow cytometric analysis. Reproductive capacity was reduced in a dose-dependent manner, with no cells forming colonies after treatment at drug concentrations of 0.5 jug ml-' and above ( Figure 5 ). In contrast, cell survival was reduced in a dose-dependent fashion to a minimum at 0.5 ,g ml-' but, beyond this level, the typical sigmoidal profile was inflected, and survival was significantly enhanced from this minimum (Figure 6) .
A further series of flow cytometric experiments were conducted, in which exposure to C-1311 was extended to 6, 12 and 24 h before transfer to drug-free medium. Essentially at + the same sequence of events was mirrored in these circumstances, although at these extended exposure times, cellular disintegration was apparent at lower drug levels and Figure 7 presents photomicrographs of HeLa cultures exposed to C-1311 over a concentration range from 0.01 to 1.0 jug ml-1 for 24 h before transfer into drug-free medium for only a further 24 h. Considerable detachment of cells from the monolayer, which we associate with cell death, was apparent in cultures dosed at 0.05 jig ml-' and extensive at 0.1 ,ug ml-1 (Figure 7c and d) . Cultures exposed to greater drug concentrations (0.5 and 1.0 ,g ml-'), although composed of apparently enlarged and misshapen cells, exhibited no 'rounded' or detached bodies and appeared relatively healthy (Figure 7e and f). We note with interest that cultures dosed at these higher levels remained largely free of cell disintegration even after a further 72 h in drug-free medium (data not shown).
Discussion
We have studied the actions of C-13 11, the lead compound in a new class of imidazoacridinone antineoplastic agents, against a human tumour line (HeLa S3), in an examination of the events associated with the lethality of these agents. First, we examined the sequence of dose-dependent cell cycle effects induced by C-1311 and found them to be typical of a DNA-damaging agent and consistent with the established pattern of cell cycle checkpoint engagement. We demonstrated that C-1311 can induce a complete preferential 'pure' G2 accumulation (i.e. G2 arrest) in HeLa cultures, representing the action of a DNA damage cell cycle checkpoint, but that the concentration range of this effect is very narrow, with elevation of the drug level inducing and (f) 1.0ygml-1 for 24h before transfer to drug-free medium for a further 24h. Bar= 501tm.
additional and increasing S-phase accumulation (Konopa, 1988) , more likely caused by a physical impediment to genomic replication than to an active response mechanism (Fornace, 1992; Liu, 1989) . This sequence of events is similar to, and induced at similar drug levels as, those observed against the L1210 murine leukaemia line (Augustin et al., 1996) , and is, therefore, consistent with our finding that the sensitivity of the L1210 line to (the growth inhibitory activity of) the compound reported by others (Cholody et al., 1992) is shared by the HeLa line.
We have also shown that normal human diploid fibroblasts (which putatively express wild-type p53 tumoursuppressor gene) exposed to C-1311 exhibit the same sequence of cycle perturbations, and at similar concentrations as HeLa cells, although in all cases a G1 phase arrest accompanied these late cycle accumulations. This observation is consistent with the demonstration that cells which express wild-type p53 exhibit both GI and G2 arrest after exposure to DNA-damaging agents, whereas those which lack p53 expression, express a mutant form of the p53 gene, or fail to accumulate p53 protein (as do HeLa cells), typical of many tumour cell lines (Hollstein et al., 1991; Levine et al., 1991) , arrest only in G2, reflecting loss of the GI DNA damagesensitive cell cycle checkpoint (Fritsche et al., 1993; Kastan et al., 1991 Kastan et al., , 1992 Kuerbitz et al., 1992) .
An identical sequence of cycle perturbations was exhibited by cultures of HeLa cells and normal fibroblasts treated with the recognised topoisomerase II inhibitor, etoposide (Liu, 1989) , albeit at 10-fold higher concentrations than with C-1311 (unpublished observations).
Cell cycle arrest is not a biological end point, however, and it is the fate of the arrested cell which determines the ultimate treatment outcome. Flow cytometric analysis of cellular DNA content can reveal both cell cycle position and, as judged by the appearance of cells with a less than G, DNA (Mosmann, 1983) , clearly reflected the enhanced survival of cultures exposed to high doses of compound, relative to treatments at lower levels, as did two other independent metabolic measures: neutral red uptake and [3H]leucine incorporation (data not shown). Clonogenic assays cannot discriminate between arrested cells which do not form colonies and those which are killed outright (Lanks and Lehman, 1990) ; taken together, these observations identify the surviving population as non-reproductive, but metabolically active.
We consider our findings entirely consistent with the proposition that events normally associated with the G2/M transition are implicated in the mechanisms of cell death, and indeed provide further evidence in its support. That cell death is associated with activation (dephosphorylation) of the p34CdC2 kinase distal to G2 arrest (Lock et al., 1994; Lock Concentration dependent lethality of C-1311 J Lamb and DN Wheatley 1365 and Keeling, 1993; Lock and Ross, 1990b) , suggests that this particular mode of cell killing is dependent upon assembly of the primed mitotic machinery, specifically the hyperphosphorylated p34cdc2/cyclin B complex. This mechanism relies, therefore, upon cell cycle progression being allowed to proceed to the temporal location of complex assembly. Given that human cells synthesise cyclin B and form p34`dc2 complexes comparatively late in cycle (Steinmann et al., 1991) , cellular derangements which prevent progression to this point, such as the impediment to genomic replication owing to high doses of DNA-damaging agents observed in this study and by others (Konopa, 1988) , will prevent assembly of the complex. Although cellular damage secondary to pharmacological insult may be more severe, cell death induced by kinase activation is prevented, just as by artificial inhibition of complex assembly by cyclin B antisense oligonucleotides (Fotedar et al., 1995) .
Cells treated with high drug levels, which initially exhibited an S-phase delay, and appeared protected from cell death, did eventually attain G2 DNA content but still did not succumb. Instead we found a tendency to initiate a second round of DNA synthesis in the absence of mitosis (see >G2 cells Figure 4, 1.0 ug ml-l at 48 h and 96 h), similar to behaviour exhibited by cells surviving doxorubicin exposure (Lanks and Lehman, 1990) . It is reported that HeLa cells subject to inhibition of DNA synthesis also down-regulate protein synthesis due to a strict integrational coupling between nuclear and cytoplasmic events, and hence do not accumulate cyclin B when so arrested (Kung et al., 1993) . It may be that excessive delay in genomic replication is associated with an inability to accumulate sufficient levels of the protein for mitosis (or cell death), resulting in survival and entry to the higher ploidy state observed. Studies are underway to confirm directly the failure of these cells to accumulate or associate cyclin B and p34`dI2* Application of our findings to the clinical exploitation of DNA-damaging chemotherapeutic agents suggests that maximum anti-tumour efficacy can only be attained within a narrow dose range, and that doses in excess of this level may not confer any advantage in terms of tumour cell kill. Cells surviving a DNA damage insult, which presumably harbour a pool of induced genetic mutations, can regain proliferative capacity (Sorensen and Eastman, 1988b) but may also become 'adapted' to their lesions and resume cell cycle progression before completion of repair (Weinert and Lydall, 1993) . The treatment thus becomes associated with an enhanced probability that more malignant or drug-resistant clones will appear, and hence with a poorer outcome. Only those treatments which culminate in frank tumour cell death are compatible with the pursuit of selective antineoplastic chemotherapy.
It is still unclear whether cell death associated with mitotic kinase activation results directly from failure to execute a normal mitosis, and whether in some circumstances this mitotic catastrophe merely resembles programmed cell death (i.e. by causing the features of apoptosis), or if proteins phosphorylated by p34Cdc2/cyclin B are positive mediators of a true, specific, inducible cell death programme. The latter is predicted by a modification of the 'dual signal' hypothesis (Evan and Littlewood, 1993) , in which progressional control events simultaneously activate both the proliferative process and a cell death mechanism as a 'fail safe' against uncontrolled or inappropriate proliferation. Relaxation of the normal downstream inhibition of the cell death programme, on detection of unrepaired genomic damage, provides a physiological suicide response after checkpoint failure rather than death as a consequence of mitosis attempted in the presence of critical damage with the attendant danger of survival with gross chromosomal derangement.
What is clear, however, is that this pathway frequently constitutes the predominant route to the death of tumour cells, at least in vitro, following induced DNA damage. Whatever the detail, downstream failure of the premitotic AP4 (Kaufmann et al., 1995) , facilitates the genetic instability characteristic of cancer (Hartwell and Kastan, 1994; Hartwell, 1992; Weinert and Lydall, 1993) , but also predisposes these cells with a vulnerability to DNA damage. Given, additionally, that checkpoint function appears inversely related to increasing transformed phenotype (Kung et al., 1990) , recent indications that cells with defective p53 are more susceptible to G2 checkpoint abrogation (Fan et al., 1995; Powell et al., 1995; Russell et al., 1995) , and the marked susceptibility of the highly deranged HeLa line (this study), future work will attempt to correlate G2 checkpoint stringency with sensitivity to DNA-damaging agents to examine possible differential lethality towards tumour cells.
It has recently been demonstrated that G, arrest mediated by superimposition of wild-type p53 function upon a transformed cell line markedly reduced the extent of DNA damage-induced cell death, coincident with a decrease in the proportion of cells reaching the G2 phase (Malcomson et al., 1995) , and that abolition of G, arrest through disruption of normal p53 function sensitised a human cancer line to DNA damage, coincident with an increase in the proportion of cells reaching G2 (Fan et al., 1995) . These findings further highlight the importance of G2 checkpoint targeting for maximum chemotherapeutic advantage, especially in cell types which do not exhibit a propensity to undergo p53-dependent programmed cell death. On this basis, the influence of G, checkpoint fidelity upon the prevalence of cell killing from the G2 compartment will also be examined in terms of both chemoresistance of tumour cells, and protection of normal cells, like the fibroblasts in this study, from deleterious consequences of exposure to these noxious agents.
